Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 2 3Phase 1 3

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 3

Interventions

pembrolizumab 257Cyclophosphamide 241Specimen Handling 198fludarabine 173Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 119Carboplatin 97Radiotherapy 92Paclitaxel 85venetoclax 82Cisplatin 80Gemcitabine 79fludarabine phosphate 78Injections 68Ipilimumab 64Dexamethasone 61atezolizumab 59Bevacizumab 58Cetuximab 57Radiation 55Fluorouracil 55Azacitidine 55durvalumab 54Radiosurgery 52Temozolomide 47Rituximab 44Oxaliplatin 44Irinotecan 43Docetaxel 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Electroporation × 1 year × Clear all
NCT06378047 2026-02-09

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
2 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03484299 2025-10-29

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

University of Louisville

Phase 1 Recruiting
20 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06205849 2025-07-25

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

University of California, San Diego

Phase 1 Recruiting
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡